CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options.
BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
类器官技术近年来取得了显著进展。然而,当前的癌症类器官方法主要涉及从 2D 癌细胞或细胞簇创建 3D 肿瘤组织,主要用于癌症研究目的,旨在探究肿瘤发生的相关分子和细胞机制。这些方法是研究驱动的,并非针对临床应用量身定制,无法为个体患者提供个性化信息。PSO 填补了临床驱动且省时方法的空白,用于为癌症患者选择个性化治疗。
在癌症治疗中,每一分钟都至关重要。由于癌细胞不断突变导致其行为难以预测,每位癌症患者的情况都是独特的,对特定药物或治疗可能有效也可能无效。寻找有效疗法的过程可能耗时较长,但癌症患者没有时间进行反复试验。因此,迫切需要一种能快速生成与患者相关的类器官用于疗法选择的新技术。
利用新的类器官技术,通过特殊溶解从癌症患者获取的肿瘤组织中的间质,我们在一天内实现了创建患者特异性类器官(PSO)的工作。
PSO 的特性反映了其各自原始体内肿瘤组织的特性,并可用于进行各种体外药物敏感性测试,以确定对患者最有效的临床治疗。此外,PSO 还可帮助评估免疫细胞疗法的疗效。
Utilizing the new organoid technology by specially dissolving the mesenchyme in tumor tissues acquired from cancer patients, we realized the work of creating patient-specific organoids (PSO) within one day.
PSO properties reflect those of its respective original in vivo tumor tissue and can be utilized to perform various in vitro drug sensitivity tests to identify the most effective clinical treatment for patients. Additionally, PSO can aid in assessing the efficacy of immune cell therapies. DISCUSSION: Organoid technology has advanced significantly in recent years. However, current cancer organoid methods involve creating 3D tumor tissue from 2D cancer cells or cell clusters, primarily for cancer research purposes aimed at investigating related molecular and cellular mechanisms of tumor development. These methods are research-driven, not tailored towards clinical applications, and cannot provide personalized information for individual patients. PSO filled the gap of clinic-driven and time-saving method for the personalized therapies selecting to the cancer patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。